Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2000-06-01
2002-09-10
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S185000, C540S145000
Reexamination Certificate
active
06448239
ABSTRACT:
FIELD OF THE INVENTION
The invention relates in general to substituted metallic complexes and more particularly to substituted porphyrin-, porphyrazine-, texaphyrin-, salen-, or corrole-metal complexes.
BACKGROUND OF THE INVENTION
The peroxynitrite ion (ONOO
−
) is a potent oxidant formed by the combination of nitric oxide (NO) and the superoxide anion (O
2
)
−
. NO has been shown to be generated by numerous cell types, such as macrophages, neutrophils, hepatocytes and endothelial cells. The direct combination of NO with O
2
produces the peroxynitrite ion (ONOO
−
), which decomposes rapidly under physiological conditions to oxidizing intermediates. These oxidizing intermediates can damage biological targets.
Pathological consequences associated with damage to biological targets can include the oxidizing or nitrating of proteins, lipids and DNA. ONOO
−
crosses lipid membranes at a rate significantly faster than the rates of other known oxidants, indicating that this oxidant can travel distances of cellular dimensions. Thus, even in the presence of biological membranes, ONOO
−
can have free access to cellular interiors. ONOO
−
is also known to nitrate tyrosine residues in proteins, and to oxidize sulfhydryls, methionines and macromolecules such as, for example, metalloenzymes, DNA, and lipids.
In light of this reactivity, ONOO
−
has been implicated in a variety of diseases. These diseases include, e.g., neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, stroke, AIDS dementia and Hungington's disease; heart diseases such as atherosclerosis; chronic inflammation and autoimmune diseases such as arthritis, inflammatory bowel disease, and acute respiratory disease syndrome; cancer; ischemia-reperfusion injury; septic shock; and chronic rejection of renal grafts.
SUMMARY OF THE INVENTION
The invention is based in part on the discovery of novel substituted metallic complexes that are effective peroxynitrite decomposition catalysts. Preferred catalysts have one or more of the properties of high catalytic activity, high stability and enhanced lifetime in the blood pool, advantageous tissue distribution, and low toxicity. The peroxynitrite decomposition catalysts can be used to treat a variety of conditions and diseases, including those known to involve the accumulation of the oxidant peroxynitrite.
Accordingly, in one aspect the invention provides a novel substituted metallic complex falling within one of formulas I through VII, as set forth in the Detailed Description of the Invention below. Compounds falling within the formula include various substituents, e.g., those including one or more polyethylene glycol (PEG) moieties.
Also provided are methods of treating neurodegenerative disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, stroke, AIDS dementia and Hungington's disease; atherosclerosis; chronic inflammation; autoimmune diseases, including arthritis, inflammatory bowel disease, and acute respiratory disease syndrome; cancer; ischemia-reperfusion injury; septic shock; and chronic rejection of renal grafts in mammals by administering to a mammal in need of such treatment a pharmaceutically effective amount of a compound according to one of formulas I-VII.
In a further aspect, the invention also includes a method for the production of compounds according to any one of formulas I-VII.
Also provided are pharmaceutical compounds including the compounds of the invention and a pharmaceutically acceptable carrier.
In yet another aspect, the invention includes the use of compounds disclosed herein as diagnostic probes to determine the involvement of peroxynitrite and other reactive oxygen and nitrogen species in disease states both in vivo and in vitro.
The details of one or more embodiments of the invention are set forth in the accompanying description below. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated by reference.
REFERENCES:
patent: 5109016 (1992-04-01), Dixon et al.
patent: 5284647 (1994-02-01), Niedballa et al.
patent: 5663393 (1997-09-01), Jacobsen et al.
patent: 5801229 (1998-09-01), Sessler et al.
patent: 6002026 (1999-12-01), Groves et al.
patent: 6087493 (2000-07-01), Wheelhouse et al.
patent: 6103714 (2000-08-01), Fridovich et al.
patent: 6245758 (2001-06-01), Stern et al.
patent: 0 524 161 (1993-01-01), None
patent: WO 93/16721 (1993-09-01), None
patent: WO 95/31197 (1995-11-01), None
Jakobs et al., Chemical Abstracts, vol. 126:324503, 1997.*
Cheng et al., Chemical Abstracts, vol. 112:146393, 1990.*
Wu et al., Chemical Abstracts, vol. 113:143962, 1990.*
Wheelhouse et al., Chemical Abstracts, vol. 129:170516, 1998.*
Hunt et al., Chemical Abstracts, vol. 128:123775, 1997.*
Woehrle et al., Chemical Abstracts, vol. 123:354281, 1995.*
Tong et al., Chemical Abstracts, vol. 120:94146.*
Lee, et al., Bioorganic & Medicinal Chemistry Letters, 7:2913-2918 (1997).
Lee, et al., J. Am. Chem. Soc., 120:7493-7501 (1998).
Misko, et al., J. of Biol. Chem., 273:15646-15652 (1998).
International Search Report dated Dec. 13, 2000.
Hunt, J. A., Lee, J., Groves, J. T., Amphiphilic peroxynitrite decomposition catalysts in liposomal assemblies, Chem. Biol. 1997, 4 (11): 845-58.
Groves, J.T., Artificial Enzymes. The importance of being selective; Nature, 1997, 389: 329-30.
Groves, J.T., Peroxynitrite: reactive, invasive and enigmatic, Chem. Biol., 1999, 3:226-235.
Reedijk, J., Medicinal applications of heavy-metal compounds, Chem. Biol., 1999, 3:236-240.
Pasternack, R.F., et al., Solution Properties of Tetrakis-(4-N-Methyl)Pyridylporphineiron(III), J. Inorg. Nucl. Chem. 1977, 39: 1865-1870.
Groves John T.
Moeller Suzanne M.
Elrifi, Esq. Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo PC
Raymond Richard L.
Trustees of Princeton University
LandOfFree
Peroxynitrite decomposition catalysts and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peroxynitrite decomposition catalysts and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peroxynitrite decomposition catalysts and methods of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2851113